The XBI has plunged 27% since Donald Trump won the election, leaving the public markets an ugly mess for a biotech industry ...

Roche plans $50B investment in US over 5 years for R&D and manufacturing, including 4 new facilities and expansions, amid ...

AstraZeneca/Daiichi's Enhertu plus Perjeta shows better progression-free survival vs standard care in first-line HER2+ ...

Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication ...

Gilead's antibody-drug conjugate Trodelvy combined with Merck's Keytruda reduced the risk of disease progression or death in ...

Alvogen plans to fight a court decision that could significantly delay its ability to bring a generic version of Bausch ...

The FDA made two de­ci­sions on Re­gen­eron’s best-sell­ing drugs Fri­day, hand­ing down one ap­proval and one re­jec­tion.

Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its ...

A hot antibody discovery team in China has signed its second US biotech deal in less than six months, marking the latest sign ...

Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory ...

US brand-name drugs use foreign ingredients, with Europe supplying 43% of APIs, as Trump administration considers 25% tariffs ...

The 340B drug discount program may move under the purview of CMS, according to a leaked HHS restructuring document reviewed ...